Global Human Microbiome Therapeutics Market 2018-2022
SKU ID :TNV-11372734 | Published Date: 27-Dec-2017 | No. of pages: 106Description
TOC
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
• Market outline
PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market segmentation analysis
PART 06: MARKET SIZING
• Market definition
• Market size and forecast
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: PIPELINE LANDSCAPE
PART 09: MARKET SEGMENTATION BY THERAPEUTIC APPLICATION
• Comparison by therapeutic application
• Gastrointestinal disorders
• Immunological conditions
• Others
• Market opportunity by therapeutic application
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Comparison by region
• Human microbiome therapeutics market in Americas
• Human microbiome therapeutics market in EMEA
• Human microbiome therapeutics market in APAC
• Key leading countries
• Market opportunity by region
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
• Increase in industry-academia collaboration
• Increasing investments by venture capitalists
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive analysis
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ENTEROME Bioscience
• Rebiotix
• Seres Therapeutics
• Vedanta Biosciences
PART 17: APPENDIX
• List of abbreviations
List of Exhibits
Exhibit 01: Microbiome by host
Exhibit 02: Common prebiotics
Exhibit 03: Major sources of prebiotics
Exhibit 04: Benefits of probiotics
Exhibit 05: Parent market
Exhibit 06: Global human microbiome therapeutics market: Characteristics
Exhibit 07: Global human microbiome therapeutics market: Segmentation
Exhibit 08: Market definition: Inclusions and exclusions checklist
Exhibit 09: Market size 2017
Exhibit 10: Validation techniques employed for market sizing 2017
Exhibit 11: Global human microbiome therapeutics market 2017-2022 ($ millions)
Exhibit 12: Global human microbiome therapeutics market: Year-over-year growth
Exhibit 13: Five forces analysis 2017
Exhibit 14: Five forces analysis 2022
Exhibit 15: Bargaining power of buyers
Exhibit 16: Bargaining power of suppliers
Exhibit 17: Threat of new entrants
Exhibit 18: Threat of substitutes
Exhibit 19: Threat of rivalry
Exhibit 20: Market condition: Five forces 2017
Exhibit 21: Pipeline landscape
Exhibit 22: Key clinical trials
Exhibit 23: Global human microbiome therapeutics market by therapeutic application 2017-2022 (% share)
Exhibit 24: Comparison by therapeutic application
Exhibit 25: Global human microbiome therapeutics market by gastrointestinal disorders 2017-2022 ($ millions)
Exhibit 26: Global human microbiome therapeutics market by gastrointestinal disorders: Year-over-year growth 2018-2022
Exhibit 27: Global human microbiome therapeutics market by immunological conditions 2017-2022 ($ millions)
Exhibit 28: Global human microbiome therapeutics market by immunological conditions: Year-over-year growth 2018-2022
Exhibit 29: Global human microbiome therapeutics market by others 2017-2022 ($ millions)
Exhibit 30: Global human microbiome therapeutics market by others: Year-over-year growth 2018-2022
Exhibit 31: Market opportunity by therapeutic application
Exhibit 32: Customer landscape
Exhibit 33: Global human microbiome therapeutics market by region 2017-2022 (% share)
Exhibit 34: Regional comparison
Exhibit 35: Human microbiome therapeutics market in Americas 2017-2022 ($ millions)
Exhibit 36: Human microbiome therapeutics market in Americas: Year-over-year growth
Exhibit 37: Human microbiome therapeutics market in EMEA 2017-2022 ($ millions)
Exhibit 38: Human microbiome therapeutics market in EMEA: Year-over-year growth 2018-2022
Exhibit 39: Human microbiome therapeutics market in APAC 2017-2022 ($ millions)
Exhibit 40: Human microbiome therapeutics market in APAC: Year-over-year growth 2018-2022
Exhibit 41: Top Asian countries in terms of population with diabetes (millions)
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity by region
Exhibit 44: Global obesity facts 2014
Exhibit 45: Factors causing changes in human microbiome
Exhibit 46: Antibiotic resistance steps
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Competitive structure analysis of global microbiome therapeutics market
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: ENTEROME Bioscience: Overview
Exhibit 54: ENTEROME Bioscience: Business segments
Exhibit 55: ENTEROME Bioscience: Organizational developments
Exhibit 56: ENTEROME Bioscience: Geographic focus
Exhibit 57: ENTEROME Bioscience: Segment focus
Exhibit 58: ENTEROME Bioscience: Key offerings
Exhibit 59: Rebiotix: Overview
Exhibit 60: Rebiotix: Business segments
Exhibit 61: Rebiotix: Organizational developments
Exhibit 62: Rebiotix: Geographic focus
Exhibit 63: Rebiotix: Segment focus
Exhibit 64: Rebiotix: Key offerings
Exhibit 65: Seres Therapeutics: Overview
Exhibit 66: Seres Therapeutics: Business segments
Exhibit 67: Seres Therapeutics: Organizational developments
Exhibit 68: Seres Therapeutics: Geographic focus
Exhibit 69: Seres Therapeutics: Segment focus
Exhibit 70: Seres Therapeutics: Key offerings
Exhibit 71: Vedanta Biosciences: Overview
Exhibit 72: Vedanta Biosciences: Business segments
Exhibit 73: Vedanta Biosciences: Organizational developments
Exhibit 74: Vedanta Biosciences: Geographic focus
Exhibit 75: Vedanta Biosciences: Segment focus
Exhibit 76: Vedanta Biosciences: Key offerings
Tables & Figures
Companies
ENTEROME Bioscience, Rebiotix, Seres Therapeutics, Vedanta Biosciences, Bristol-Myers Squibb, Johnson & Johnson, and Takeda Pharmaceutical.
- PRICE
-
$2500$4000